Health Care & Life Sciences » Biotechnology | Molecular Partners AG

Molecular Partners AG | Balance Sheet

Fiscal year is January-December. All values CHF Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
96,126.50
188,382.60
215,390.00
180,226.00
141,061.00
98,958
Total Accounts Receivable
11,537.20
3,198.80
1,344.00
844.00
1,153.00
51,615
Other Current Assets
127.00
379.70
126.00
485.00
311.00
2,746
Total Current Assets
107,790.70
191,961.10
216,860.00
181,555.00
142,525.00
153,319
Net Property, Plant & Equipment
2,298.00
2,029.90
2,518.00
2,496.00
1,871.00
1,455
Intangible Assets
22.60
27.30
17.00
47.00
27.00
382
Total Assets
110,111.30
194,018.30
219,395.00
184,098.00
144,423.00
155,156
Accounts Payable
243.30
343.90
1,231.00
1,027.00
716.00
Income Tax Payable
723.70
-
-
-
-
Other Current Liabilities
21,773.00
21,758.50
25,215.00
14,738.00
13,425.00
Total Current Liabilities
22,740.00
22,102.40
26,446.00
15,765.00
14,141.00
Provision for Risks & Charges
1,736.50
3,080.70
4,202.00
5,723.00
4,014.00
Other Liabilities
37,319.10
20,356.40
36,952.00
26,815.00
9,539.00
Total Liabilities
61,795.60
45,539.40
67,600.00
48,303.00
27,694.00
Common Equity (Total)
48,315.70
148,478.90
151,795.00
135,795.00
116,729.00
Total Shareholders' Equity
48,315.70
148,478.90
151,795.00
135,795.00
116,729.00
Total Equity
48,315.70
148,478.90
151,795.00
135,795.00
116,729.00
Liabilities & Shareholders' Equity
110,111.30
194,018.30
219,395.00
184,098.00
144,423.00

About Molecular Partners

View Profile
Address
Wagistrasse 14
Zurich Zurich 8952
Switzerland
Employees -
Website http://www.molecularpartners.com
Updated 07/08/2019
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun and Michael Tobias Stumpp on November 23, 2004 and is headquartered in Zurich, Switzerland.